ArticleJournal of chest surgery2026
Upstaging Risk and Prognosis of Clinical T2-3N0M0 Esophageal Squamous Cell Carcinoma Patients after a Curative Esophagectomy: A Propensity Score-Matched Analysis.
Article in Journal of chest surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Commentary: Balancing Upfront Surgery and Neoadjuvant Therapy in Clinically Node-Negative T2-3 Esophageal Squamous Cell Carcinoma.Journal of chest surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemoradiation therapy (nCRT) has survival benefits for patients with cT1N1 or cT2-3N0-1 esophageal squamous cell carcinoma (ESCC), but heterogeneous disease behavior has been observed in node-negative tumors. This study aimed to investigate the risk of upstaging and the efficacy of upfront esophagectomy compared with nCRT followed by surgery in patients with cT2-3N0 ESCC. Methods: ESCC patients treated at Taipei Veterans General Hospital, Taiwan, between January 2010 and December 2022 were retrospectively reviewed. Patients who underwent upfront surgery (n=72) and those who received neoadjuvant therapy (n=36) were included in this analysis on an intention-to-treat basis after propensity score matching. Comparisons of TNM (tumor, node, and metastasis) classification shifts between patients who underwent upfront surgery and those who received neoadjuvant therapy, as well as primary outcomes including overall survival (OS) and recurrence-free survival (RFS), were analyzed. Results: Among patients who underwent upfront surgery, 6 (16.7%) in the cT2 group and 10 (27.8%) in the cT3 group had occult lymph node (LN) metastasis. Most patients (77.4%) who received neoadjuvant therapy experienced downstaging; however, there were no significant differences in OS (5-year OS: 53.8% vs. 51.6%, p=0.666) or RFS (5-year RFS: 48.6% vs. 44.8%, p=0.864) compared with upfront surgery. No significant differences were observed before propensity score matching for either OS (p=0.809) or RFS (p=0.856). Conclusion: Upfront esophagectomy in patients with cT2-3N0 ESCC provides comparable survival outcomes, despite the higher risk of upstaging and occult LN metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.